Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 11, 2013
Dr. Eric Winer talks about his study showing women with small, HER2-positive breast tumors who received a combination of a less harsh chemotherapy drug such as paclitaxel, along with Herceptin (a targeted therapy), were unlikely to have the cancer recur within a few years of treatment. The research was presented at the annual San Antonio Breast Cancer Symposium in San Antonio, Texas.